Scotland · NHS Scotland MSAN
Levemir® (insulin detemir) FlexPen® 100units/ml solution for injection 3ml
MSAN(2025)41 · Level 2 · issued 25 Aug 2025
What the notice states
The supply position for each affected product, as recorded in the notice — read the full signed PDF above for the clinical advice and actions.
| Product | Position | Resupply |
|---|---|---|
| Valid until: noted products are being discontinued | Discontinued | — |
| being discontinued; stock is anticipated to be exhausted by the end of 2026. | Discontinued | — |
| 11. As insulin glargine is available in two strengths, these products must be prescribed BY | Available | — |
| Abasaglar® KwikPen® In stock Cannot support | Available — cannot support uplift | — |
| Abasaglar® cartridges In stock Cannot support | Available — cannot support uplift | — |
| FlexTouch® early January 2026 Cannot support | Available — cannot support uplift | — |
| Human isophane Humulin I® KwikPen® In stock Cannot support | Available — cannot support uplift | — |
| acting) Humulin I® cartridges In stock Cannot support | Available — cannot support uplift | — |
| Clinical Guideline: Discontinuation of Levemir® • SmPC Toujeo® | Discontinued | — |
| Registration for access to the website is available to UK healthcare professionals and | Available | — |
From the NHS Scotland notice PDF (linked above); dates and “valid until” text are as stated, fuzzy wording kept as written. Scotland is covered separately from England — see methodology. Not an official NHS service, and not clinical advice — follow the guidance issued to your pharmacy.